High Blood Eosinophil and YKL-40 Levels, as Well as Low CXCL9 Levels, are Associated with Increased Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

References

• Crisafulli E, Guerrero M, Chetta A, Torres A. Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Eur Respir J. 2016;48(1):279–281. doi:10.1183/13993003.00426-2016
   PubMedGoogle Scholar
• Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418–1428. doi:10.1056/NEJMsa0803563
   PubMed Web of Science ®Google Scholar
• Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(8):1009–1017. doi:10.1164/rccm.201709-1852OC
   PubMed Web of Science ®Google Scholar
• Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: european COPD Audit. Eur Respir J. 2016;47(1):113–121. doi:10.1183/13993003.01391-2014
   PubMed Web of Science ®Google Scholar
• Ko FW, Dai DL, Ngai J, et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology. 2011;16(4):617–624. doi:10.1111/j.1440-1843.2010.01921.x
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2):1900651. doi:10.1183/13993003.00651-2019
   PubMed Web of Science ®Google Scholar
• Singh D, Bafadhel M, Brightling CE, et al. Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;202(5):660–671. doi:10.1164/rccm.201912-2384PP
   PubMed Web of Science ®Google Scholar
• Vashi MT, Willoughby JL, Quinn SJ, Tran BT. Eosinophilic chronic obstructive pulmonary disease: implications for exacerbations, readmissions, and treatment. Am J Respir Crit Care Med. 2019;199(1):110–112. doi:10.1164/rccm.201802-0328RR
   PubMedGoogle Scholar
• Kong CW, Wilkinson TMA. Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res. 2020;6(2):00325–02019. doi:10.1183/23120541.00325-2019
   PubMedGoogle Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2017). Global Initiative Chron Obstructive Lung Dis. 2017.
   Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC
   PubMed Web of Science ®Google Scholar
• Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–2047.e2010. doi:10.1016/j.jaci.2018.04.010
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-0
   PubMed Web of Science ®Google Scholar
• Casanova C, Celli BR, De-torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50(5):1701162. doi:10.1183/13993003.01162-2017
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–373. doi:10.1016/j.chest.2016.10.003
   PubMed Web of Science ®Google Scholar
• Håkansson KEJ, Ulrik CS, Godtfredsen NS, et al. High suPAR and low blood eosinophil count are risk factors for hospital readmission and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:733–743. doi:10.2147/COPD.S229904
   PubMed Web of Science ®Google Scholar
• Li Q, Larivée P, Courteau J, et al. Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths. Int J Chron Obstruct Pulmon Dis. 2019;14:331–341. doi:10.2147/COPD.S187375
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150(2):320–328. doi:10.1016/j.chest.2016.01.026
   PubMed Web of Science ®Google Scholar
• Izuhara K, Conway SJ, Moore BB, et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med. 2016;193(9):949–956. doi:10.1164/rccm.201510-2032PP
   PubMed Web of Science ®Google Scholar
• Berry A, Busse WW. Biomarkers in asthmatic patients: has their time come to direct treatment? J Allergy Clin Immunol. 2016;137(5):1317–1324. doi:10.1016/j.jaci.2016.03.009
   PubMed Web of Science ®Google Scholar
• Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009;206(5):1149–1166. doi:10.1084/jem.20081271
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zheng T, Homer RJ, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science. 2004;304(5677):1678–1682. doi:10.1126/science.1095336
   PubMed Web of Science ®Google Scholar
• Tong X, Wang D, Liu S, et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:409–418. doi:10.2147/COPD.S152655
   PubMed Web of Science ®Google Scholar
• Henrot P, Prevel R, Berger P, Dupin I. Chemokines in COPD: from implication to therapeutic use. Int J Mol Sci. 2019;20(11):2785. doi:10.3390/ijms20112785
   PubMed Web of Science ®Google Scholar
• Costa C, Rufino R, Traves SL, Lapa ESJR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest. 2008;133(1):26–33. doi:10.1378/chest.07-0393
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49(12):1429–1433. doi:10.1016/S0895-4356(96)00271-5
   PubMed Web of Science ®Google Scholar
• Alqahtani JS, Njoku CM, Bereznicki B, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(156):190166. doi:10.1183/16000617.0166-2019
   PubMed Web of Science ®Google Scholar
• Nuñez A, Miravitlles M. Preventing readmissions of COPD patients: more prospective studies are needed. Eur Respir Rev. 2020;29(156):200097. doi:10.1183/16000617.0097-2020
   PubMed Web of Science ®Google Scholar
• Thorn GW, Renold AE, Wilson DL, et al. Clinical studies on the activity of orally administered cortisone. N Engl J Med. 1951;245(15):549–555. doi:10.1056/NEJM195110112451501
   PubMed Web of Science ®Google Scholar
• Kang MJ, Yoon CM, Nam M, et al. Role of chitinase 3-like-1 in interleukin-18-induced pulmonary type 1, type 2, and type 17 inflammation; alveolar destruction; and airway fibrosis in the murine lung. Am J Respir Cell Mol Biol. 2015;53(6):863–871. doi:10.1165/rcmb.2014-0366OC
   PubMed Web of Science ®Google Scholar
• Tang H, Fang Z, Sun Y, et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J. 2010;35(4):757–760. doi:10.1183/09031936.00034409
   PubMed Web of Science ®Google Scholar
• Gasperini S, Marchi M, Calzetti F, et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol. 1999;162(8):4928–4937.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Okazawa T, Uga H, Kurata H, Mori A. Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthma. Allergy. 2019;74(12):2515–2518. doi:10.1111/all.13924
   PubMed Web of Science ®Google Scholar
• Nukui Y, Yamana T, Masuo M, et al. Serum CXCL9 and CCL17 as biomarkers of declining pulmonary function in chronic bird-related hypersensitivity pneumonitis. PLoS One. 2019;14(8):e0220462. doi:10.1371/journal.pone.0220462
   PubMed Web of Science ®Google Scholar
• Fulkerson PC, Zimmermann N, Brandt EB, et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc Natl Acad Sci U S A. 2004;101(7):1987–1992. doi:10.1073/pnas.0308544100
   PubMed Web of Science ®Google Scholar
• Buhl R, Korn S, Menzies-Gow A, et al. Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma. J Allergy Clin Immunol Pract. 2020;8(8):2630–2639.e2636. doi:10.1016/j.jaip.2020.03.038
   PubMed Web of Science ®Google Scholar
• Pavord ID, Corren J. Biomarkers of type 2 airway inflammation in airway disease: and then there were two. J Allergy Clin Immunol Pract. 2020;8(8):2640–2642. doi:10.1016/j.jaip.2020.04.047
   PubMed Web of Science ®Google Scholar
• Konstantelou E, Papaioannou AI, Loukides S, et al. Serum periostin in patients hospitalized for COPD exacerbations. Cytokine. 2017;93:51–56. doi:10.1016/j.cyto.2017.05.007
   PubMed Web of Science ®Google Scholar
• Carpaij OA, Muntinghe FOW, Wagenaar MB, et al. Serum periostin does not reflect type 2-driven inflammation in COPD. Respir Res. 2018;19(1):112. doi:10.1186/s12931-018-0818-8
   PubMedGoogle Scholar
• Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758–766. doi:10.1164/rccm.201408-1458OC
   PubMed Web of Science ®Google Scholar
• Mertens TCJ, van der Does AM, Kistemaker LE, Ninaber DK, Taube C, Hiemstra PS. Cigarette smoke differentially affects IL-13-induced gene expression in human airway epithelial cells. Physiol Rep. 2017;5(13):e13347. doi:10.14814/phy2.13347
   PubMedGoogle Scholar